TrialSignal
Clinical trial intelligence report
Parallel Controlled Study of Epstein-Barr Virus Antibody and Epstein-Barr Virus DNA for Nasopharyngeal Carcinoma Screening in the High-risk Population
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jul 28, 2026
Report code
NCT05447169-Jul 28, 2026
NCT ID
NCT05447169
Status
RECRUITING
Phase
registry-stage
Sponsor
Sun Yat-sen University
Executive brief
Investment-Ready Snapshot
Parallel Controlled Study of Epstein-Barr Virus Antibody and Epstein-Barr Virus DNA for Nasopharyngeal Carcinoma Screening in the High-risk Population is a registry-stage clinical asset sponsored by Sun Yat-sen University in Nasopharyngeal Carcinoma. SEO and diligence focus: EBV antibodies test, EBV DNA test, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT05447169
Indication
Nasopharyngeal Carcinoma
Modality
protein therapy
Target
EBV antibodies test, EBV DNA test
Intervention
EBV antibodies test, EBV DNA test
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.